JP2021520353A - ヒト臍帯組織由来の間葉系間質細胞を使用して脳性麻痺および低酸素性虚血性脳症を処置する方法 - Google Patents

ヒト臍帯組織由来の間葉系間質細胞を使用して脳性麻痺および低酸素性虚血性脳症を処置する方法 Download PDF

Info

Publication number
JP2021520353A
JP2021520353A JP2020554078A JP2020554078A JP2021520353A JP 2021520353 A JP2021520353 A JP 2021520353A JP 2020554078 A JP2020554078 A JP 2020554078A JP 2020554078 A JP2020554078 A JP 2020554078A JP 2021520353 A JP2021520353 A JP 2021520353A
Authority
JP
Japan
Prior art keywords
msc
hct
patient
administered
study
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020554078A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019195554A5 (https=
JP2021520353A5 (https=
Inventor
ジョアン カーツバーグ，
ジョアン カーツバーグ，
ジェシカ サン，
ジェシカ サン，
アレン ソング，
アレン ソング，
チャールズ マイケル コットン，
チャールズ マイケル コットン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Duke University
Original Assignee
Duke University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duke University filed Critical Duke University
Publication of JP2021520353A publication Critical patent/JP2021520353A/ja
Publication of JPWO2019195554A5 publication Critical patent/JPWO2019195554A5/ja
Publication of JP2021520353A5 publication Critical patent/JP2021520353A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/35—Fat tissue; Adipocytes; Stromal cells; Connective tissues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2020554078A 2018-04-04 2019-04-04 ヒト臍帯組織由来の間葉系間質細胞を使用して脳性麻痺および低酸素性虚血性脳症を処置する方法 Pending JP2021520353A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862652818P 2018-04-04 2018-04-04
US62/652,818 2018-04-04
PCT/US2019/025796 WO2019195554A1 (en) 2018-04-04 2019-04-04 Methods of treating cerebral palsy and hypoxic-ischemic encephalopathy using human umbilical cord tissue-derived mesenchymal stromal cells

Publications (3)

Publication Number Publication Date
JP2021520353A true JP2021520353A (ja) 2021-08-19
JPWO2019195554A5 JPWO2019195554A5 (https=) 2022-04-11
JP2021520353A5 JP2021520353A5 (https=) 2022-04-11

Family

ID=68101217

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020554078A Pending JP2021520353A (ja) 2018-04-04 2019-04-04 ヒト臍帯組織由来の間葉系間質細胞を使用して脳性麻痺および低酸素性虚血性脳症を処置する方法

Country Status (11)

Country Link
US (1) US20210361716A1 (https=)
EP (1) EP3773624A4 (https=)
JP (1) JP2021520353A (https=)
KR (1) KR20210021946A (https=)
CN (1) CN112236152A (https=)
AU (1) AU2019247383B2 (https=)
BR (1) BR112020020288A2 (https=)
CA (1) CA3096037A1 (https=)
IL (1) IL277732A (https=)
SG (1) SG11202009800SA (https=)
WO (1) WO2019195554A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024075676A1 (ja) * 2022-10-03 2024-04-11 キッズウェル・バイオ株式会社 脳性まひの予防又は治療剤
WO2025100424A1 (ja) * 2023-11-10 2025-05-15 国立大学法人 東京大学 急性脳症治療剤及び急性脳症の治療方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1803193A (zh) * 2005-01-13 2006-07-19 中山大学 骨髓来源的间质干细胞用于制备治疗缺氧缺血性脑性瘫痪的制剂的用途
US20070128722A1 (en) * 2005-12-05 2007-06-07 Industrial Technology Research Institute Human mesenchymal stem cells and culturing methods thereof
US20170042944A1 (en) * 2014-04-21 2017-02-16 Anthrogenesis Corporation Treatment of conditions and complications in infants
WO2016019332A1 (en) * 2014-07-29 2016-02-04 Ingeneron, Inc. Method and apparatus for recovery of umbilical cord tissue derived regenerative cells and uses thereof
WO2017144552A1 (en) * 2016-02-22 2017-08-31 Centauri Biotech. S.L. Pharmaceutical or veterinary cell compositions comprising mesenchymal stromal cells (mscs) and dimethyl sulfoxide (dmso)
JP7126703B2 (ja) * 2016-05-24 2022-08-29 国立大学法人 東京大学 臍帯由来細胞を含む脳障害の治療剤
KR101973284B1 (ko) * 2017-01-16 2019-04-29 사회복지법인 삼성생명공익재단 신생아 ｈｉｅ 치료용 조성물

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CASE REPORTS IN TRANSPLANTATION, vol. 2013, JPN6023002581, 2013, pages 146347, ISSN: 0005070805 *
CYTOTHERAPY, vol. 17, JPN6023002580, 2015, pages 224 - 231, ISSN: 0005070804 *
JOURNAL OF NEUROSCIENCE RESEARCH, vol. 92, JPN6023002583, 2014, pages 35 - 45, ISSN: 0005070807 *
PLOS ONE, vol. 10, no. 3, JPN6023002582, 2015, pages 0120893, ISSN: 0005070806 *
STEM CELL RESEARCH & THERAPY, vol. 12, JPN6023002579, 2021, pages 152, ISSN: 0004973814 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024075676A1 (ja) * 2022-10-03 2024-04-11 キッズウェル・バイオ株式会社 脳性まひの予防又は治療剤
WO2025100424A1 (ja) * 2023-11-10 2025-05-15 国立大学法人 東京大学 急性脳症治療剤及び急性脳症の治療方法

Also Published As

Publication number Publication date
AU2019247383B2 (en) 2025-11-27
EP3773624A4 (en) 2022-01-12
WO2019195554A1 (en) 2019-10-10
AU2019247383A1 (en) 2020-10-29
KR20210021946A (ko) 2021-03-02
EP3773624A1 (en) 2021-02-17
BR112020020288A2 (pt) 2021-01-12
SG11202009800SA (en) 2020-11-27
IL277732A (en) 2020-11-30
US20210361716A1 (en) 2021-11-25
CA3096037A1 (en) 2019-10-10
CN112236152A (zh) 2021-01-15

Similar Documents

Publication Publication Date Title
Baak et al. Feasibility and safety of intranasally administered mesenchymal stromal cells after perinatal arterial ischaemic stroke in the Netherlands (PASSIoN): a first-in-human, open-label intervention study
Díez-Tejedor et al. Reparative therapy for acute ischemic stroke with allogeneic mesenchymal stem cells from adipose tissue: a safety assessment: a phase II randomized, double-blind, placebo-controlled, single-center, pilot clinical trial
Bruschettini et al. Stem cell‐based interventions for the prevention of morbidity and mortality following hypoxic‐ischaemic encephalopathy in newborn infants
DeLong et al. Vaginal microbiota transplantation: the next frontier
Lanci et al. Dystocia in the standardbred mare: a retrospective study from 2004 to 2020
Zhou et al. Feasibility and safety of autologous cord blood derived cell administration in extremely preterm infants: a single-centre, open-label, single-arm, phase I trial (CORD-SaFe study)
Sato et al. Safety and tolerability of a Muse cell-based product in neonatal hypoxic-ischemic encephalopathy with therapeutic hypothermia (SHIELD trial)
AU2019247383B2 (en) Methods of treating cerebral palsy and hypoxic-ischemic encephalopathy using human umbilical cord tissue-derived mesenchymal stromal cells
Tai-MacArthur et al. The theoretical basis of in utero hematopoietic stem cell transplantation and its use in the treatment of blood disorders
EP3773486B1 (en) Umbilical cord tissue-derived mesenchymal stromal cells for use in the treatment of autism spectrum disorders
Dytfeld et al. Road to clinical implementation of CAR-T technology in Poznań
Phillips et al. Perinatal and neonatal implications of sickle cell disease
Zhou et al. Early neurodevelopment of extremely preterm infants administered autologous cord blood cell therapy: secondary analysis of a nonrandomized clinical trial
US20200016213A1 (en) Methods of Treating Cerebral Palsy Using High Dose Allogeneic Umbilical Cord Blood
Robinson et al. Chromosome aberrations and LSD: a controlled study in 50 psychiatric patients
Kosaryan et al. Demographic data of patients with β-thalassemia major recorded in the electronic system in the north of Iran, 2016.
HK40044465A (en) Methods of treating cerebral palsy and hypoxic-ischemic encephalopathy using human umbilical cord tissue-derived mesenchymal stromal cells
Shamim et al. The promise of autologous and allogeneic cellular therapies in the clinical trials of autism spectrum disorder
US20250312383A1 (en) Human umbilical cord blood for use in alleviating fatigue
Saitoh et al. Safety and feasibility of allogeneic sibling cord blood infusion in Japanese children with cerebral palsy: A single-center pilot study
John et al. The Pediatric Clinician’s Approach to Referring Children and Adolescents with Sickle Cell Disease for Potentially Curative Therapies
Diao et al. Clinical trial of intrathecal injection of protein polymers for apoplexy: A protocol
MacKenzie et al. In Utero Hematopoietic Cell Transplantation in Fetuses with Alpha Thalassemia Major: A Phase 1 Clinical Trial
HK40045701A (en) Methods of treating autism spectrum disorders using human umbilical cord tissue-derived mesenchymal stromal cells
US20230210911A1 (en) Methods and materials for treating non-malignant disorders or diseases with cord blood

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220401

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220401

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230120

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230424

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230530